The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
The inspection concluded with zero form 483 observations
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
Subscribe To Our Newsletter & Stay Updated
